MaxCyte (MXCT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
GlobeNewswireNov 13 08:05 ET
BTIG Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $8
Moomoo NewsNov 12 07:31 ET · Ratings
MaxCyte Weighs Delisting From AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
TipRanksNov 8 01:00 ET
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $11
Moomoo NewsNov 7 10:31 ET · Ratings
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating, Announces Target Price $7
Moomoo NewsNov 7 09:35 ET · Ratings
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating
Moomoo NewsNov 7 08:39 ET · Ratings

Comments

Jaguar8

Sep 16 01:01

NEWS

$MaxCyte (MXCT.US)$
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenu...

Jaguar8

May 22 08:41

$MaxCyte (MXCT.US)$
NEWS
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive an...

frogoracletrading

May 8 21:54

$MXCT Support / Resistance Levels

Here are the levels to watch after the sharp move up.
Larger Image: tradingview.com...
$MaxCyte (MXCT.US)$

Moomoo Breakfast US

Apr 13, 2022 07:38

Columns Today's pre-market stock movers: DAL, JPM, NSTG, ATRS and more

Gainers:
• $Antares Pharma (ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology (SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma (AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics (BCTX.US)$ +6% (presents development details of...

12

4

102575831

Aug 27, 2021 09:06

$MaxCyte (MXCT.US)$ come riseee

1

MXCT MaxCyte

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target